LY 3002813

Drug Profile

LY 3002813

Alternative Names: LY3002183-SC; LY3002813; LY3002813-IV; N3pG-amyloid-beta Monoclonal Antibody

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 13 Dec 2017 Phase I development is ongoing in USA and Japan (SC, IV)
  • 08 Dec 2017 Eli Lilly plans a phase II trial in Alzheimer's disease (Combination therapy, In the elderly) in December 2017 (NCT03367403)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease in Japan (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top